Stapokibart Injection for atopic dermatitis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, prospective observational study evaluating Stapokibart Injection for adults with atopic dermatitis. Participants receive the treatment as prescribed by their physician prior to joining the study, and outcomes are observed over time. The study focuses on safety and potential efficacy signals in real-world use. Location is at Peking University People's Hospital in Beijing, led by Chengdu Kangnuoxing Biopharma, Inc.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Trial participants aged 18 years or older at baseline, with no restrictions on gender.
* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.

Exclusion Criteria:

* Known history of allergic reaction to Stapokibart Injection.
* Trial participants currently or plan participating in any interventional clinical trial.
* Trial participants with hematologic malignancies.
* Women with pregnant.
* Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Qian Jia
• Email: clinicaltrial@keymedbio.com
• Phone: 028-88610620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults

  This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Hangzhou, Zhejiang · NCT07895615

• PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body

  This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.

  Recruiting at 6 sites Phase 2 Prana Therapies Inc · Botany, New South Wales and 8 other locations · NCT07810777

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Global Health Look at Atopic Dermatitis

  A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.

  Recruiting University of Zurich · Zurich · NCT07659756

• S-4321 in adults with autoimmune or immune-mediated diseases

  This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.

  Recruiting at 2 sites Phase 1 Seismic Therapeutic AU Pty Ltd · Charlestown, New South Wales and 1 other locations · NCT07455578

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.